Investigators from the Veteran’s Affairs Center for Innovation to Implementation and Stanford University searched publication databases through June 2022 for observational studies about methamphetamine-associated heart failure.
Your search for major depressive disorder returned 74 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Investigators looked into which treatment fared better for patients with anxiety disorders: a mindfulness-based stress reduction intervention or escitalopram.
Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.
Researchers measured associations between trauma and child psychiatric disorders in a birth cohort in Brazil.
A team of investigators evaluated the prevalence of noncancer-related pain conditions among adult individuals with attention-deficit/hyperactivity disorder.
As people living with HIV begin to age, their risk of developing HIV-associated cognitive decline increases. A specific training program to help patients with HIV with speed of processing (SOP) may help stall those effects.
Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.
Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.
Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.
The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.
Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.
Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.
For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.
This prospective, multi-center, open-label trial, CAN-BIND-1 was conducted between 2012 and 2017.
Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
Researchers examined correlations between suicidal ideation and suicide attempt history in patients with treatment-resistant depression following ketamine infusion.
Researchers explored the neurobiology related to reward-based reinforcement learning and psychomotor retardation in patients in remission from MDD.
Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.
Investigators sought to determine if response to sympathetic nerve blocks may be predictive of response to ketamine infusion.
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
Major depressive episodes reduce visual contrast suppression among patients with depressive disorders, a study shows.
Ensemble is an AI-powered digital mental health coach app designed to address the symptoms of MDD or GAD.
To learn more about the impact of depression therapy on anxiety symptoms, researchers conducted a randomized controlled clinical trial with teenagers to compare the results of personalized depression therapy to a program that does not match their risk factors.
Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.
This retrospective cohort study evaluated patient data from patients aged 50 years or older who received an acute course of ECT between 2011 and 2019 and were evaluated for cognition and depression outcomes on the basis of baseline cognitive function.